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The enzyme DNA topoisomerase IIα (TOP2α) induces covalent complexes with DNA 
and produces transient double-strand DNA breaks crucial for processes such as replication and 
normal chromosomal dysjunction at mitosis. TOP2α is an important target for clinically effective 
anticancer agents, such as etoposide (VP-16), since these drugs stabilize the otherwise short-
lived enzyme-DNA covalent complexes, thereby inducing cytotoxic DNA damage. However, the 
efficacy of these agents is limited by chemoresistance. Our lab has characterized acquired 
resistance to VP-16 in human leukemia K562 cells. The cloned resistant cell line, K/VP.5, 
contains reduced levels of TOP2α compared to parental K562 cells. The goal of this project is to 
test the hypothesis that TOP2α levels are decreased in K/VP.5 cells, in part, through miRNA-
mediated mechanisms. 
Pooled miRNA qPCR profiling experiments were performed to investigate the expression 
levels of ~500 miRNAs in K562 and K/VP.5 cells. hsa-miR-9-3p and -5p (miR-9-3p and -5p) 
were overexpressed in K/VP.5 cells compared to K562 cells. The TOP2α 3ʹ-UTR harbors 
putative miRNA recognition elements (MRE) for these miRNAs. Therefore, these miRNAs were 
chosen for further study. To assess post-transcriptional regulation of TOP2α by miRNAs, a dual 
luciferase reporter plasmid harboring the entire 3ʹ-UTR of TOP2α mRNA (998 bp) was 
constructed (psiTOP2α/UTR). Transfection with psiTOP2α/UTR demonstrated decreased 
luciferase expression in K/VP.5 compared with K562 cells, suggesting altered post-
transcriptional regulation in resistant cells. K562 cells that were co-transfected with 
psiTOP2α/UTR and miR-9-3p or -5p mimic resulted in a statistically significant decrease in 
luciferase expression only for miR-9-5p. Mutating the putative miR-9-5p seed sequence 
prevented the decrease in luciferase activity, demonstrating a direct interaction of this miRNA 
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with the MRE of TOP2α. Immunoblotting for TOP2α in K562 cells transfected with miR-9-3p or 
-5p mimic resulted in decreased TOP2α protein compared to mock transfected K562 cells.  
Conversely, immunoblotting for TOP2α in K/VP.5 cells transfected with miR-9-3p or -5p 
inhibitor resulted in an increase of TOP2α protein, strongly suggesting a role for both miRNAs 
in acquired resistance to VP-16. 
Our findings indicate that miR-9-3p and -5p regulate TOP2α expression levels. In 
addition, results presented here contribute to the elucidation of chemoresistance mechanisms and 






The enzyme human DNA topoisomerase IIα (TOP2α) induces covalent complexes with 
DNA and produces transient double-strand DNA breaks crucial for processes such as replication 
and normal chromosomal dysjunction at mitosis (1). The TOP2α enzyme exists as a homodimer 
whose monomers utilize a tyrosine active site as a nucleophile to begin a reversible 
transesterification reaction with the 5ʹ-nucleobase scissile sites on the phosphate backbones of 
the top and bottom strands of DNA (1). This cleavage and subsequent religation of DNA allows 
for the relaxation of specific DNA entanglements (2-5). Highly proliferative cells are dependent 
on TOP2α to relieve torsional stress resulting from DNA topological entanglements during 
replication (6). Hence TOP2α has been utilized as an important target in cancer (1,7-9). Type IIA 
topoisomerase interfacial inhibitors, such as VP-16, stabilize the otherwise short-lived enzyme-
DNA complexes by interjecting themselves between the four base regions of the scissile break 
sites generated by TOP2α (9,10). This action inhibits the religation of double-strand breaks and 
the disengagement of TOP2α from DNA. Programmed cell death ensues due to an aggregation of 
double-strand DNA breaks (9). 
Our lab has characterized acquired resistance to VP-16 in human leukemia K562 cells. 
This cloned resistant cell line, K/VP.5, was found to contain one-fifth the level of TOP2α protein 
and one-third the level of the corresponding mRNA compared to parental K562 cells (11) 
(Figure 1). Previously, we showed that one determinant of this observed decrease is due to 
alternative RNA processing of TOP2α that results in a C-terminal truncated isoform. We also 
demonstrated that this shortened TOP2α isoform (TOP2α/90) elicits resistance via a dominant 
negative effect on full-length TOP2α (TOP2α/170) (12). However, alternative RNA processing 
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did not account for the entire decrease in TOP2α. Thus, other potential determinants of gene 
regulation were investigated. 
MicroRNA (miRNA) mediated post-transcriptional gene silencing is an established 
mechanism of genetic regulation (13). miRNAs are a family of small non-coding RNAs that are 
21-25 nucleotides in length. They originate as precursor pri-miRNAs that are transcribed by 
RNA polymerase II. During processing, the pri-miRNA is shortened into a miRNA duplex. One 
strand of the miRNA duplex is selected to be incorporated into the RNA-induced silencing 
complex (RISC) (14). The miRNA-RISC complex (miRISC) is guided by a seed sequence 
(spanning from position 2 to 8 at the 5ʹ end of the miRNA) that base pairs to a specific miRNA 
recognition element (MRE) typically harbored in the 3ʹ-untranslated region (3ʹ-UTR) of a target 
mRNA (15,16). MREs are also found in the 5ʹ-untranslated region (5ʹ-UTR) and coding region 
(CDS) of mRNAs (17-19). Upon binding to the mRNA, miRISC will subsequently reduce the 
expression of the target mRNA by blocking the ribosome from translating the mRNA or by 
initiating the degradation of the mRNA. Blocking the ribosome or degrading the mRNA by 
miRISC is determined by the type of Argonaut (AGO) present in miRISC, the degree of 
complementarity between the miRNA and mRNA, and the accessibility of the MRE (15,20,21). 
In the majority of mammalian cells, miRISC serves to block rather than degrade the mRNA (22).  
In this study, we have examined the hypothesis that TOP2α expression can be regulated 
by miRNAs in K562 cells. Given the low expression of TOP2α in K/VP.5 cells, miRNAs 
overexpressed in K/VP.5 cells with corresponding MREs in the 3ʹ-UTR of TOP2α were of 
particular interest. Experimental analyses demonstrated that hsa-miR-9-3p and -5p (miR-9-3p 




Figure 1. A: K562 cells were ~20-fold resistant to VP-16 compared to parental K562 cells in a 
48-hour grown inhibition assay. B-C: The expression levels of TOP2α protein (immunoblot) and 







Materials and Methods 
Plasmids 
A 998-bp fragment encoding for the entire TOP2α 3′-UTR was PCR amplified by 
utilizing sense (5′-AGGCGATCGCTCGAGAATGTGAGGCGATTATTTTAAGTAA-3′) and 
antisense (5′-ATTCCCGGGCTCGAGTGGGTTGCAATGTTTAGAACATT-3′) primers using 
standard procedures with a proofreading polymerase, CloneAmp HiFi, from Takara Bio Inc. (cat. 
No. 639298; Kusatsu, Shiga, Japan). Genomic DNA from K562 cells was used as template. A 
psiCHECK-2 vector purchased from Promega Corporation (cat. No. C8021; Madison, WI, USA) 
was linearized with restriction digest enzymes NotI and XhoI from New England Biolabs (cat. 
No. R0189S, R0146S; Ipswich, MA) according to the manufacturer’s protocol. The TOP2α      
3′-UTR PCR product was subcloned into the linearized psiCHECK-2 vector utilizing an In-
Fusion HD Cloning Kit (cat. No. 638916; Takara Bio Inc.) according to the manufacturer’s 
protocol. The TOP2α 3′-UTR sequence cloned into the multiple cloning site (MCS) of 
psiCHECK-2 was expressed as fusions to the C-terminus of Renilla luciferase. Plasmid DNA 
was isolated from recombinant colonies and sequenced to ensure authenticity. The resulting 
recombinant plasmid was designated psiTOP2α/UTR.  
The mutant reporter construct psiTOP2α/UTR-mut-5p was generated utilizing the 
psiTOP2α/UTR vector as template and mutating the miR-9-5p MRE (located at 703-709 bp) 
harbored in the TOP2α 3′-UTR using a Q5 Site-Directed Mutagenesis kit from New England 
Biolabs (cat. No. E0554S) and following the manufacturer’s instructions. The primers utilized 
for mutagenesis were sense (5′-AAGCGTGGAGAAACCAATTTCTAAG-3′) and antisense                                                
(5′-GAGATTCAGACTCAGAGGCAGC-3′). The nucleotides that were mutated are shown in 
bold print. The mutation of the miR-9-5p seed sequence was confirmed by dideoxy chain 
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termination sequencing. The mutant reporter construct psiTOP2α/UTR-mut-3p was generated in 
the same manner as psiTOP2α/UTR-mut-5p, but at (466-471 bp) with the primers sense                   
(5′-GAAACTGGTTCTAGTACAGATAC-3′) and antisense                                                      
(5′-TTCTATCTGATGGTAAATTATG-3′). Lastly, transformed bacterial cultures were grown 
and each reporter construct was isolated with a Qiagen Plasmid Midi Kit (cat. No. 12143; 
Hilden, Germany). 
Cell Culture 
Human K562 leukemia cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Corning, Manassas, VA) supplemented with 10% fetal bovine serum (FS).  Cloned 
etoposide-resistant K562 cells (K/VP.5) were generated by continuous incubation in 0.5 µM 
etoposide followed by isolation by limiting dilution, as previously described (23). K/VP.5 cells 
were maintained in DMEM/10% FBS with 0.5 µM etoposide added every other week.  
Luciferase Assay 
K562 and K/VP.5 cells (in exponential phase growth) were washed and lysed with 
passive lysis buffer (cat. No. E1941; Promega), and firefly and Renilla luciferase activities were 
determined by using the Dual-Luciferase Reporter Assay System (cat. No. E1910; Promega) 
with a Synergy H1 Hybrid Multi-Mode Reader (BioTek, Winooski, VT, USA). Renilla luciferase 
expression in the psiCHECK-2 vector is generated via an SV40 promoter. Firefly luciferase in 
this vector is generated via a HSV-TK promoter and has been specifically designed to be an 
intraplasmid transfection normalization reporter. The Renilla luciferase signal was therefore 





Total RNA was isolated from K562 and K/VP.5 cells using PureZOL RNA Isolation 
Reagent from Bio-Rad Laboratories (cat No. 7326880; Hercules, CA, USA). Digestion of DNA 
was then performed using TURBO DNAase from Invitrogen (cat. No. AM2238; Carlsbad, CA, 
USA). Mature human miR-9-3p, -5p, and RNU48 were quantified by utilizing TaqMan assay 
kits specific for each RNA molecule from Applied Biosysems (cat. No. 002231 (miR-9-3p), 
000583 (miR-9-5p), 001006 (RNU48), Foster City, CA, USA). Ten ng of total RNA underwent 
reverse transcription with miR-9-3p, -5p, and RNU48 antisense primers in a 15 µl reaction 
according to manufacturer instructions. Quantitative real-time PCR (20 µl reaction) was 
performed by using 1.33 µl of cDNA with primer/probe sets specific for miR-9-3p, -5p, and 
RNU48. Gene expression was calculated relative to RNU48.  
RNA isolation and DNase treatment for downstream TOP2α mRNA quantification via 
qPCR was performed as outlined above. Random primed cDNA was synthesized from one µg 
RNA, according to the manufacturer’s protocol, using the High Capacity cDNA Reverse 
Transcription Kit (cat. No. 4368814; Applied Biosystems). Quantitative real-time PCR (20 µl 
reaction) was performed by using 5 µl of a 1:5 dilution of cDNA with primer/probe sets specific 
for TOP2α and TBP (Hs01032136_m1, Hs00427620_m1; Applied Biosystems). Gene 
expression was calculated relative to TBP.  
Western blot analysis 
K562 and K/VP.5 cells were pelleted and washed in phosphate-buffered saline. After 
washing, 1.5 million cells were lysed in 2x Laemmli sample buffer (cat. No. 1610737; Bio-Rad 
Laboratories) containing 5% β-mercaptoethanol, and boiled at 100 °C for 5 minutes. DNA was 
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sheared using a sonicator (Tekmar, Mason, OH, USA) at 35 W three times in 10 second 
intervals. Samples were electrophoresed on a NuPAGE 4-12% Bis-Tris gel from ThermoFisher 
(cat. No. NP0322BOX; Waltham, MA, USA). Duplicate samples were run with an equal amount 
of protein (16.6 µg) loaded into each well. Protein was transferred to a polyvinylidene difluoride 
(PVDF) membrane (Bio-Rad Laboratories) using a semidry electroblotter (ThermoFisher). The 
PVDF membrane was then sectioned. The 75-250 kDa portion was labeled by overnight 
incubation at 4 °C with rabbit polyclonal antibodies raised against the N-terminal sequence of 
human TOP2α (cat. No. ab74715; Abcam, Cambridge, MA; used at 1:1000 dilution). The 25-75 
KDa portion was labeled by overnight incubation at 4 °C with a glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mouse monoclonal antibody (1:5000; cat. No. sc-47724; Santa Cruz 
Biotechnology, Santa Cruz, CA). PVDF membranes were subsequently incubated at room 
temperature for 1.5 hours with a donkey anti-rabbit or donkey anti-mouse secondary antibody 
respectively (1:8000 dilution) (Jackson ImmunoResearch, West Grove, PA). Antibody-labeled 
TOP2α and GAPDH were detected using the Immun-Star horseradish peroxidase 
Chemiluminescence Kit (cat. No. 170-5040; Bio-Rad Laboratories). All immunoassay images 
were taken with the ChemiDoc XRS+ imaging system and analyzed with ImageLab software 
(Bio-Rad Laboratories).  
Transfection with Mimic and Inhibitors 
K562 and K/VP.5 cells (5 x 105 in 5 mL per condition) were transfected with dual 
luciferase plasmids (psiTOP2α/UTR, psiTOP2α/UTR-3pmut, psiTOP2α/UTR-5pmut) utilizing 1 
µg of the respective plasmid, 5.5 µl Lipofectamine 3000 (cat. No. L3000008; Invitrogen), and 
250 µl Opti-Mem Medium (cat. No. 31985062; Invitrogen). miRNA mimic (cat. No. 
MIMAT0000441 (miR-9-3p); MIMAT0000442 (miR-9-5p); 4464058 (miRNA mimic negative 
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control #1); Ambion, Foster City, CA, USA) and inhibitor (MIMAT0014627 (miR-9-3p); 
MIMAT0036307 (miR-9-5p); 4464076 (miRNA inhibitor negative control #1); Ambion) 
transfections were similarly performed, but achieving a total concentration of 25 nM of the 
respective mimic or inhibitor). Forty-eight hours after transfection, cellular extracts were 







Scheme 1. TOP2α 3ʹ-UTR was inserted into the psiCHECK-2 plasmid containing dual luciferase 
capability. Renilla luciferase served as the reporter gene regulated by the TOP2α 3ʹ-UTR. Firefly 





miR-9-3p and -5p are Overexpressed in K/VP.5 Cells 
Utilizing the methods reported above, pooled qPCR was performed to investigate 
differentially expressed miRNAs in K562 versus K/VP.5 cells using total RNA. Over 500 
miRNAs were analyzed. The top five miRNAs overexpressed in K/VP.5 cells were hsa-miR-9-
5p, hsa-miR-375-3p, hsa-miR-9-3p, hsa-miR-149, and hsa-miR-383 (Fig 2A). This data from the 
initial pooled qPCR was validated for miR-9-3p and -5p in K/VP.5 cells through qPCR using 
total RNA (Fig. 2B).  
miRNA-mediated genetic regulation results when a miRNA recognizes a specific MRE 
on a mRNA and subsequently inhibits its translation or initiates its degradation (15,16). 
Bioinformatics tools have been developed to predict miRNA/mRNA binding (24,25). TargetScan 
was used to predict putative MREs located in the 3ʹ-UTR of TOP2α and additional MREs were 
predicted manually. miR-9-3p and -5p were chosen for further study as both had putative MREs 
in the 3ʹ-UTR of TOP2α, indicating a high probability of binding to TOP2α mRNA versus other 
miRNAs that were overexpressed in K/VP.5 cells without MREs in the 3ʹ-UTR of TOP2α 
(15,16). The type of MRE for miR-9-3p and -5p were assessed to aid in determining the 
likelihood of the predicted MREs as being functionally important in the regulation of TOP2α 
expression with respect to either miRNA’s seed sequence. miR-9-3p had a 6mer seed sequence 
and miR-9-5p had a more robust 7mer-m8 seed sequence (Fig. 2C). Additionally, a context score 
was calculated for miR-9-5p to further predict its functionality. A context score is based on MRE 
site-type, 3ʹ pairing, local AU effect, position of the 3ʹ-UTR, target site abundance, and seed-
pairing stability (24). A context score below -0.30 was used as a cutoff as previously described 
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(26) and the context score for miR-9-5p was -0.03. No context score was provided for miR-9-3p 
as its site type was predicted manually. 
Differential Regulation of TOP2α 3′-UTR in K562 and K/VP.5 Cells 
To investigate if the 3′-UTR of TOP2α is affected differently in K/VP.5 cells compared 
to K562 cells, a dual luciferase reporter assay was employed. The justification for using this 
assay is that the binding of a given miRNA to its distinct MRE will repress reporter protein 
production, thereby reducing luciferase activity. Accordingly, the entire 3ʹ-UTR (998-bp) was 
subcloned directly downstream of the hR-luc open reading frame. This construct was labeled 
psiTOP2α/UTR and contains the aforementioned MREs for miR-9-3p and -5p. To assess 
differential regulation of TOP2α 3ʹ-UTR, psiTOP2α/UTR was transfected into K562 and K/VP.5 
cells and luciferase activity was measured. Luciferase activity was decreased in K/VP.5 cells 
compared to K562 cells (Fig. 3). This result suggests that some factor(s) in resistant cells must be 
acting on the 3′-UTR of TOP2α to cause the observed decrease in luciferase activity. 
miR-9-5p Directly Affects TOP2α 3′-UTR 
To investigate whether miR-9-3p or -5p can regulate TOP2α expression, the same 
luciferase reporter assay system was utilized. K562 cells have low amounts of miR-9-3p and-5p 
(compared to K/VP.5 cells) and are therefore appropriate to study these miRNAs through gain-
of-function analyses. K562 cells were co-transfected with psiTOP2α/UTR and either miR-9-3p 
or -5p mimic. Cells were grown for 48 hours and lysed while in log phase. Additionally, RNA 
was isolated and qPCR was performed to assure that mimic transfection resulted in miRNA 
overexpression. Both miR-9-3p and -5p levels increased significantly in K562 cells (P<0.05) 
when transfected with the respective mimic with no cross-over effect (no increase in the non-
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transfected mimic level) (Fig. 4A). Luciferase activities were subsequently measured (Fig. 4B). 
These experiments demonstrated that a statistically significant decrease (P<0.05) in luciferase 
activity resulted when K562 cells were transfected with miR-9-5p. Luciferase activity was not 
decreased significantly upon transfection with miR-9-3p. 
To validate that miR-9-5p interacted with the predicted MRE in the 3ʹ-UTR of TOP2α, an 
additional luciferase reporter construct was generated in which the entire 7-bp MRE 
(CCAAAGA), specific to the 5ʹ seed sequence of miR-9-5p, was mutated (AAGCGUG). The 
mutant construct was labeled psiTOP2α/UTR-mut-5p. Subsequent co-transfection of K562 cells 
with psiTOP2α/UTR-mut-5p and miR-9-5p mimic resulted in no significant difference in 
luciferase activity between the two conditions (Fig. 4C). These results support direct binding of 
miR-9-5p to the MRE on the 3’UTR of TOP2α. For completeness, another luciferase reporter 
construct was generated in which the entire 6-bp MRE (CUUUAU), specific to the 5ʹ seed 
sequence of miR-9-3p, was mutated (GAAACU). The mutant construct was labeled 
psiTOP2α/UTR-mut-3p. Subsequent co-transfection of K562 cells with psiTOP2α/UTR-mut-3p 
and miR-9-3p mimic resulted in no significant difference in luciferase activity between the two 
conditions (Fig. 4D). However, since miR-9-3p did not statistically significantly decrease 
luciferase activity of psiTOP2α/UTR in K562 cells (Fig. 4B), it is not likely that miR-9-3p binds 
directly to its putative MRE in the 3ʹ-UTR of TOP2α. 
miR-9-3p and -5p Lower Expression of TOP2α in K562 Cells 
If TOP2α mRNA is an authentic target of miR-9-3p or -5p, then manipulation of the 
endogenous expression of miR-9-3p or -5p should result in predictable changes in TOP2α 
protein levels. For instance, a gain of function analysis through overexpression of a given 
miRNA should lead to a decrease in target protein expression. Conversely, a loss of function 
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analysis through transfection of a given miRNA inhibitor should lead to greater target protein 
expression; via decreased translational repression or mRNA degradation due to an inhibition of 
the function of specific mature miRNAs. In this study, gain-of-function experiments were 
performed in K562 cells (low miR-9 levels) to evaluate effects of overexpression of miR-9-5p 
and miR-9-3p on TOP2α protein expression.  Conversely, loss-of-function experiments were 
performed in K/VP.5 cells (high miR-9 levels) to evaluate effects of forced expression of 
inhibitors of miR-9-5p and miR-9-3p on TOP2α protein expression.   
 Gain-of-function experiments were performed in K562 cells by transfecting these cells 
with 25 nM miR-9-3p or -5p mimic, and TOP2α levels were subsequently measured by 
immunoblotting assays. TOP2α levels in cells transfected with miR-9-3p or -5p mimic resulted 
in statistically significant decreases (51.7% and 60.4% respectively) compared to control 
(P<0.05) (Fig. 5A).  
 Loss-of function experiments were performed in K/VP.5 cells by transfecting these cells 
with 25 nM miR-9-3p or -5p inhibitor, and TOP2α levels were subsequently measured by 
immunoblotting assays. TOP2α levels in cells transfected with miR-9-3p or -5p inhibitor resulted 
in statistically significant increases (239.3% and 255.3% respectively) compared to control 
(P<0.05) (Fig 5B).  
The potential mechanism by which miR-9-3p and -5p reduces TOP2α levels was assessed 
by real-time qPCR. RNA isolated from K562 and K/VP.5 cells, transfected with mimic or 
inhibitor, respectively, was assayed for TOP2α mRNA. Transfection with miR-9-3p or -5p 
mimics or inhibitors did not decrease TOP2α steady state mRNA levels (Fig. 5C) suggesting that 
miR-9 posttranscriptional effects are at the level of translation as is reported in the literature for 



























miR-9-3p miR-9-5pN = 3 N = 3
Figure 2. A: miRNAs are overexpressed in K/VP.5 cells compared to K562 cells. B: miR-9-
3p and -5p overexpression in K/VP.5 cells compared to K562 cells was validated. C: miR-9-















































Figure 3. Luciferase activity generated from the psiTOP2α/UTR vector was reduced in K/VP.5 






























Figure 4. A: Transfection of miR-9-3p or –5p mimics resulted in overexpression of these 
miRNAs in K562 cells. B: Transfection of K562 cells with miR-9-3p or miR-9-5p mimic 
resulted in decreased luciferase activity for psiTOP2α/UTR only with miR-9-5p mimic. C: miR-
9-5p mimic had no effect when the MRE for miR-9-5p was mutated. D: miR-9-3p mimic had no 
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Figure 5. A: miR-9-3p overexpression in K562 cells resulted in a 51.7% decrease in TOP2α. 
miR-9-5p overexpression in K562 cells resulted in a 60.4% decrease in TOP2α. B: miR-9-3p 
inhibition in K/VP.5 cells resulted in a 239.3% increase in TOP2α. miR-9-5p inhibition in 
K/VP.5 cells resulted in a 255.3% increase in TOP2α. C: Forced expression of miR-9-3p or -5p 
mimics in K562 cells did not affect TOP2α expression. Forced expression of miR-9-3p or -5p 
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Discussion and Conclusion 
  
 miRNAs are estimated to regulate more than 60% of protein-coding genes in humans 
post-transcriptionally through binding to specific MREs typically harbored in the 3ʹ-UTR of a 
target mRNA (13). Due to their importance in gene regulation, dysregulation of miRNAs can 
have an impact on a variety of physiological functions including cell proliferation, apoptosis, 
development, and metabolism (27).  Specifically, miR-9-3p and -5p are implicated in a plethora 
of disease states (28-31). In cancer, miR-9-3p and -5p have been shown to have diverse roles by 
acting as either tumor suppressors by targeting oncogenes or as oncogenic molecules by 
targeting tumor suppressors (32). For example, it was found that miR-9-5p acts as a tumor 
suppressor in papillary thyroid cancer by targeting BRAF; malignant tumors had low miR-9-5p 
and high BRAF whereas nonmalignant tumors had the opposite (33). As an oncogenic molecule, 
in small cell lung cancer miR-9-5p was found to promote cell growth and metastasis by 
repression of TGFBR2 (34). Similar to the diverse functions of miR-9-5p, miR-9-3p was found 
to have tumor suppressor activity in hepatocellular carcinoma through targeting the TAZ 
oncogene (35). Conversely, upregulated miR-9-3p in medullary thyroid cancer was found to 
increase cell growth and inhibit apoptosis through targeting BLCAP (36). 
Dysregulation of miRNAs in cancer can also impact drug efficacy. For example, the 
abundant expression of miR-21 in cisplatin resistant epithelial ovarian cancer was found to 
increase chemoresistance through targeting PTEN (37). Acquired chemoresistance to drugs such 
as etoposide, amsacrine, doxorubicin, and mitoxantrone is partially characterized by decreased 
TOP2α expression (38,39). In this report, we have found that there is an abundant expression of 
miR-9-3p and -5p in etoposide resistant K562 cells (K/VP.5) compared to parental K562 cells 
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and that they target and decrease the expression of TOP2α, which can contribute to the resistance 
phenotype.  
Previously, we reported that K/VP.5  cells with acquired resistance to etoposide,  have 
reduced levels of TOP2α and an increase, as a result of alternative RNA processing, of a 90 kDa 
isoform of TOP2α (TOP2α/90) which heterodimerizes with full-length 170 kDa TOP2α 
(TOP2α/170) and is a determinant of drug resistance (12). Interestingly, there are novel MREs in 
the truncated TOP2α/90 isoform due to the retention of the TOP2α intron 19 (not shown). These 
unique MREs might be targeted by miRNAs more abundantly expressed in sensitive K562 cells 
where the 90 kd TOP2α isoform is less expressed (~3-fold less) compared to the resistant 
K/VP.5 cells. Investigation of miRNAs that target the 90 kDa TOP2α might further elucidate the 
role of miRNAs in resistance and therefore merits further study. Additionally, TOP2β is less 
expressed in K/VP.5 cells compared to K562 cells (11). TOP2β is also a target of VP-16 and its 
expression has been linked to the efficacy of VP-16’s genotoxic effects (40). Therefore, its 
reduction might contribute to chemoresistance. Preliminary immunoblot data suggests that 
TOP2β expression is regulated by miR-9-3p and -5p (data not shown). Investigations are 
underway to examine whether this effect is indirect or direct. 
 A miRNA’s ability to regulate gene expression post-transcriptionally is considered direct 
if it binds to an MRE on the target mRNA. Indirect effects occur by the miRNA targeting other 
gene(s) that impact the downstream expression of the gene being studied (41,42). Primarily, the 
3ʹ-UTR is targeted by miRNAs, however, there is growing evidence that the 5ʹ-UTR and CDS 
can harbor functional MREs as well (22,43). Interestingly, TOP2α mRNA does harbor miR-9-3p 
MREs in the CDS. Studies are ongoing to examine if miR-9-3p is capable of binding to these 
MREs to inhibit translation. Additionally, AGO HITS-CLIP assays, a recent method of mapping 
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MREs, has found that up to 80% of miRNA-mRNA binding in vivo is mediated through non-
canonical MREs (44). A canonical miRNA-mRNA interaction consists of the miRNA’s seed 
region (position 2-8) fully binding to the MRE in a mRNA. Non-canonical binding, that has been 
documented thus far, occurs when there are mismatches between the miRNA’s seed region and 
the MRE, known as a seed-like motif, or when a guanine at position 6 of the MRE on the mRNA 
bulges outward and allows the miRNA to fully bind, known as a nucleation bulge (45,46). The 
ability of miR-9-3p to downregulate TOP2α expression could also be attributed to non-canonical 
binding. Analysis of TOP2α 3ʹ-UTR for these sites, as well as an AGO HITS-CLIP assay using 
K562 and K/VP.5 cells are planned. 
The major findings in the present study are that miR-9-3p and -5p are overexpressed in 
K/VP.5 cells and that these miRNAs regulate TOP2α expression. miR-9-5p was found to directly 
interact with a specific MRE in the 3ʹ-UTR of TOP2α. Yet miR-9-3p was found to not interact at 
its predicted MRE, suggesting that miR-9-3p regulates TOP2α expression through indirect 
effects, an MRE in the CDS, or by non-canonical binding. Additionally, other newly discovered 
miRNAs might be overexpressed in K/VP.5 cells compared to K562 cells. These miRNAs could 
be playing a role in TOP2α expression and a robust miRNA-seq analysis is underway to examine 
the constellation of miRNAs that were previously unidentified when pooled miRNA qPCR 
analysis was performed. 
       In conclusion, many studies demonstrate the importance of TOP2α as a target of 
chemotherapies. Our lab previously demonstrated that a decrease in TOP2α through alternative 
RNA processing was a mechanism of drug resistance (35).  However, production of a truncated 
TOP2α/90 isoform alone did not seem to fully account for the decrease in full-length TOP2α/170 
and drug resistance observed.  
24 
 
 Given that the expression levels of TOP2α are important for the efficacy of topoisomerase II-
targeted drugs, it is necessary to understand the mechanisms by which TOP2α expression is 
regulated especially in acquired drug resistance. Here, experimental analyses demonstrated that 
miR-9-3p and -5p are overexpressed in etoposide resistant K562 cells and regulate the expression 
of TOP2α likely through inhibition of translation. Future studies will begin to investigate the 
functional role of miR-9-3p and -5p in chemoresistance through DNA damage, apoptosis, and 
cytotoxicity assays to elucidate the role of miR-9-3p and -5p in etoposide resistance and assess 
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